STAT3 Transcription Factor
"STAT3 Transcription Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A signal transducer and activator of transcription that mediates cellular responses to INTERLEUKIN-6 family members. STAT3 is constitutively activated in a variety of TUMORS and is a major downstream transducer for the CYTOKINE RECEPTOR GP130.
| Descriptor ID |
D050796
|
| MeSH Number(s) |
D12.644.360.024.342.300 D12.776.157.057.186.300 D12.776.476.024.430.300 D12.776.930.840.300
|
| Concept/Terms |
STAT3 Transcription Factor- STAT3 Transcription Factor
- Transcription Factor, STAT3
- LIF-Response Factor
- LIF Response Factor
- Acute-Phase Response Factor
- Acute Phase Response Factor
- Response Factor, Acute-Phase
- APRF Transcription Factor
- Transcription Factor, APRF
- Signal Transducer and Activator of Transcription 3
- IL6-Response Factor
- IL6 Response Factor
- STAT3 Protein
STAT3b Transcription Factor- STAT3b Transcription Factor
- Transcription Factor, STAT3b
- Stat3beta Transcription Factor
- Transcription Factor, Stat3beta
STAT3a Transcription Factor- STAT3a Transcription Factor
- Transcription Factor, STAT3a
- Stat3alpha Transcription Factor
- Transcription Factor, Stat3alpha
|
Below are MeSH descriptors whose meaning is more general than "STAT3 Transcription Factor".
Below are MeSH descriptors whose meaning is more specific than "STAT3 Transcription Factor".
This graph shows the total number of publications written about "STAT3 Transcription Factor" by people in this website by year, and whether "STAT3 Transcription Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 3 | 2 | 5 |
| 2008 | 6 | 4 | 10 |
| 2009 | 6 | 6 | 12 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 6 | 3 | 9 |
| 2013 | 6 | 3 | 9 |
| 2014 | 5 | 1 | 6 |
| 2015 | 10 | 3 | 13 |
| 2016 | 6 | 5 | 11 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 2 | 6 |
| 2019 | 6 | 4 | 10 |
| 2020 | 8 | 0 | 8 |
| 2021 | 4 | 1 | 5 |
| 2022 | 1 | 6 | 7 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "STAT3 Transcription Factor" by people in Profiles.
-
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity. Nature. 2025 Jul; 643(8070):219-229.
-
Selective inhibition of canonical STAT3 signaling suppresses K-ras mutant lung tumorigenesis and reinvigorates anti-tumor immunity. Front Immunol. 2025; 16:1575181.
-
Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to Clostridioides difficile infection. Cell Rep. 2025 Apr 22; 44(4):115438.
-
Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2025 Mar 17; 31(6):965-974.
-
Macrophage-mediated IL-6 signaling drives ryanodine receptor-2 calcium leak in postoperative atrial fibrillation. J Clin Invest. 2025 May 01; 135(9).
-
Small Molecule Screening Identifies HSP90 as a Modifier of RNA Foci in Myotonic Dystrophy Type 1. Mol Cell Biol. 2025; 45(6):225-237.
-
Integrated Clinical Genotype-Phenotype Characteristics of STAT3-Mutated Myeloid Neoplasms. Clin Cancer Res. 2024 Oct 15; 30(20):4681-4689.
-
LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab. 2024 Sep; 6(9):1756-1774.
-
Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 responses. J Allergy Clin Immunol. 2024 Nov; 154(5):1169-1179.
-
STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-?-induced Apoptosis in Urothelial Cancer. Anticancer Res. 2024 May; 44(5):1925-1930.